menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

How New Therapies & Patient Characteristics Guide cGVHD Treatment Sequencing

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Until recently, there were no approved therapeutic options for patients with steroid-refractory chronic graft versus host disease (cGVHD). But with the FDA approval of ibrutinib, ruxolitinib, and belumosudil, we can use these new therapies and a patient’s characteristics to guide treatment sequencing decisions in the second-line setting, ensuring optimal outcomes. Learn more with Dr. Charles Turck and Dr. Doris Ponce, Associate Attending Physician and Director of the GVHD Program (Adult BMT) at Memorial Sloan Kettering Cancer Center in New York City.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Until recently, there were no approved therapeutic options for patients with steroid-refractory chronic graft versus host disease (cGVHD). But with the FDA approval of ibrutinib, ruxolitinib, and belumosudil, we can use these new therapies and a patient’s characteristics to guide treatment sequencing decisions in the second-line setting, ensuring optimal outcomes. Learn more with Dr. Charles Turck and Dr. Doris Ponce, Associate Attending Physician and Director of the GVHD Program (Adult BMT) at Memorial Sloan Kettering Cancer Center in New York City.

Facebook Comments

Schedule16 Apr 2024